Cloning/NN
of/IN
A/ofl-linked/JJ
DNA/NN
Detected/JJ
by/IN
Restriction/NN
Landmark/NN
Genomic/JJ
Scanning/NN
of/IN
Human/JJ
Genome/NN
./.
====================
Epigenetic/JJ
alterations/NNS
are/VBP
common/JJ
features/NNS
of/IN
human/JJ
solid/JJ
tumors/NNS
,/,
though/IN
global/JJ
DNA/NN
methylation/NN
has/VBZ
been/VBN
difficult/JJ
to/TO
assess/VB
./.
====================
Restriction/NN
Landmark/NN
Genomic/JJ
Scanning/NN
(/(
RLGS/NN
)/)
is/VBZ
one/CD
of/IN
technology/NN
to/TO
examine/VB
epigenetic/JJ
alterations/NNS
at/IN
several/JJ
thousand/CC
Noft/JJ
sites/NNS
of/IN
promoter/NN
regions/NNS
in/IN
tumor/NN
genome/NN
./.
====================
To/TO
assess/VB
sequence/NN
information/NN
for/IN
Noft/JJ
sequences/NNS
in/IN
RLGS/NN
gel/NN
,/,
we/PRP
cloned/VBD
1,161/CD
unique/JJ
A/ofl-linked/JJ
clones/NNS
,/,
compromising/VBG
about/RB
60/CD
%/NN
of/IN
the/DT
spots/NNS
in/IN
the/DT
soluble/JJ
region/NN
of/IN
RLGS/NN
profile/NN
,/,
and/CC
performed/VBN
BLAT/NN
searches/VBZ
on/IN
the/DT
UCSC/NN
genome/NN
server/RB
,/,
May/NNP
2004/CD
Freeze/JJ
./.
====================
1,023/CD
(/(
88/CD
%/NN
)/)
unique/JJ
sequences/NNS
were/VBD
matched/VBN
to/TO
the/DT
CpG/NN
islands/NNS
of/IN
human/JJ
genome/NN
showing/VBG
a/DT
large/JJ
bias/NNS
of/IN
RLGS/NN
toward/IN
identifying/VBG
potential/JJ
genes/NNS
or/CC
CpG/NN
islands/NNS
./.
====================
The/DT
cloned/VBN
A/ofl-loci/NNS
had/VBD
a/DT
high/JJ
frequency/NN
(/(
71/CD
%/NN
)/)
of/IN
occurrence/NN
within/IN
CpG/NN
islands/NNS
near/JJ
the/DT
5/CD
'/``
ends/NNS
of/IN
known/JJ
genes/NNS
rather/RB
than/IN
within/IN
CpG/NN
islands/NNS
near/JJ
the/DT
3/CD
1/CD
ends/VBZ
or/CC
intragenic/JJ
regions/NNS
,/,
making/VBG
RLGS/NN
a/DT
potent/JJ
tool/NN
for/IN
the/DT
identification/NN
of/IN
gene-associated/JJ
methylation/NN
events/NNS
./.
====================
By/IN
mixing/JJ
RLGS/NN
gels/NNS
with/IN
all/DT
/Vod-linked/JJ
clones/NNS
,/,
we/PRP
addressed/VBD
151/CD
Noft/JJ
sequences/NNS
onto/IN
a/DT
standard/JJ
RLGS/NN
gel/NN
and/CC
compared/VBD
them/PRP
with/IN
previous/JJ
reports/NNS
from/IN
several/JJ
types/NNS
of/IN
tumors/NNS
./.
====================
We/PRP
hope/VBP
our/PRP$
sequence/NN
information/NN
will/MD
be/VB
useful/JJ
to/TO
identify/VB
novel/JJ
epigenetic/JJ
targets/NNS
in/IN
any/DT
types/NNS
of/IN
tumor/NN
genome/NN
====================
CpG/NN
islands/NNS
are/VBP
short/JJ
stretches/NNS
(/(
500-2000/CD
bp/NN
)/)
of/IN
genomic/JJ
DNA/NN
enriched/JJ
for/IN
the/DT
dinucleotide/NN
,/,
5'-CpG-3/NN
'/``
,/,
which/WDT
is/VBZ
the/DT
substrate/NN
for/IN
methylation/NN
by/IN
DNA/NN
methyltrans­/NN
ferases/NNS
./.
====================
While/IN
most/JJS
CpG/NN
sites/NNS
in/IN
the/DT
human/JJ
genome/NN
are/VBP
methylated/VBN
,/,
those/DT
in/IN
CpG/NN
islands/NNS
are/VBP
typically/RB
unmethy­/IN
lated/JJ
in/IN
normal/JJ
tissue/NN
./.
====================
In/IN
human/JJ
cancers/NNS
,/,
de/FW
novo/FW
methylation/NN
of/IN
CpG/NN
island/NN
sequences/NNS
is/VBZ
accompanied/VBN
by/IN
gene/NN
silencing/NN
and/CC
can/MD
serve/VB
as/IN
an/DT
alternative/JJ
to/TO
mutation/NN
or/CC
deletion/NN
in/IN
the/DT
inactivation/NN
of/IN
tumor/NN
suppressor/NN
and/CC
other/JJ
genes/NNS
./.
====================
In/IN
fact/NN
,/,
over/IN
the/DT
past/NN
several/JJ
years/NNS
many/JJ
studies/NNS
have/VBP
demonstrated/VBN
that/IN
epigenetic/JJ
alterations/NNS
are/VBP
responsible/JJ
for/IN
the/DT
development/NN
and/CC
progression/NN
of/IN
the/DT
human/JJ
cancers/NNS
(/(
Jones/NNS
and/CC
Baylin/NN
,/,
2002/CD
)/)
./.
====================
The/DT
ubiquity/NN
of/IN
DNA/NN
methylation/NN
changes/NNS
in/IN
tumori-/JJ
genesis/NN
has/VBZ
led/VBD
to/TO
a/DT
host/NN
of/IN
innovative/JJ
diagnostic/JJ
and/CC
ther­/DT
apeutic/JJ
strategies/NNS
./.
====================
Recent/JJ
advances/NNS
attest/VBP
to/TO
the/DT
promise/JJ
of/IN
DNA/NN
methylation/NN
markers/NNS
as/IN
powerful/JJ
tools/NNS
for/IN
the/DT
clin­/NN
ic/JJ
in/IN
the/DT
future/JJ
./.
====================
For/IN
many/JJ
epigenetically/RB
silenced/JJ
genes/NNS
,/,
re-expression/NN
in/IN
tumor/NN
cells/NNS
can/MD
lead/VB
to/TO
suppression/NN
of/IN
cell/NN
growth/NN
or/CC
altered/JJ
sensitivity/NN
to/TO
existing/VBG
anticancer/JJ
therapies/NNS
,/,
and/CC
small/JJ
molecules/NNS
that/WDT
reverse/JJ
epigenetic/JJ
in­/IN
activation/NN
are/VBP
now/RB
undergoing/VBG
clinical/JJ
trials/NNS
in/IN
cancer/NN
pa­/RB
tients/NNS
(/(
Momparler/NNP
et/FW
al./FW
,/,
1997/CD
;/:
Pohlmann/NNP
et/FW
al./FW
,/,
2002/CD
)/)
./.
====================
Epigenetic/JJ
changes/NNS
have/VBP
been/VBN
detected/VBN
in/IN
the/DT
peripheral/JJ
blood/NN
for/IN
almost/RB
every/RB
organ/NN
in/IN
cancer/NN
patients/NNS
(/(
Laird/JJ
,/,
2003/CD
)/)
./.
====================
Thus/RB
,/,
epigenetic/JJ
changes/NNS
are/VBP
not/RB
only/RB
potential/JJ
therapeutic/JJ
targets/NNS
because/IN
of/IN
their/PRP$
reversibility/NN
,/,
but/CC
also/RB
potential/JJ
biomarkers/NNS
that/IN
can/MD
be/VB
used/VBN
to/TO
detect/VB
and/CC
diag­/NN
nose/DT
cancer/NN
in/IN
its/PRP$
earliest/JJS
stage/NN
and/CC
to/TO
accurately/RB
assess/VBP
individual/JJ
risk/NN
(/(
Brown/JJ
and/CC
Strathdee/JJ
,/,
2002/CD
)/)
./.
====================
Restriction/NN
landmark/NN
genomic/JJ
scanning/NN
(/(
RLGS/NN
)/)
is/VBZ
a/DT
highly/RB
reproducible/JJ
two-dimensional/JJ
gel/NN
electrophoresis/NN
of/IN
genomic/JJ
DNA/NN
that/IN
allows/VBZ
the/DT
assessment/NN
of/IN
over/IN
2000/CD
loci/NNS
simultaneously/RB
,/,
when/WRB
a/DT
methylation/NN
sensitive/JJ
enzyme/NN
Noft/JJ
is/VBZ
used/VBN
as/IN
the/DT
landmark/NN
enzyme/NN
(/(
Hatada/NN
et/FW
al./FW
,/,
1991/CD
)/)
./.
====================
Tbe/DT
technique/NN
has/VBZ
been/VBN
used/VBN
for/IN
various/JJ
purposes/NNS
including/VBG
genetic/JJ
mapping/VBG
,/,
identification/NN
of/IN
novel/JJ
imprinted/JJ
genes/NNS
,/,
genomic/JJ
amplifications/NNS
,/,
regions/NNS
of/IN
hypomethylation/NN
or/CC
hypermethylation/NN
,/,
candidate/RB
tumor/NN
suppressor/NN
genes/NNS
,/,
and/CC
measuring/VBG
the/DT
degree/NN
of/IN
CpG/NN
island/CC
hypermethylation/NN
in/IN
cancer/NN
(/(
Costello/NNP
etal./FW
,/,
2000/CD
;/:
Hayashizaki/NNP
etal./FW
,/,
1993/CD
;/:
Kim/NNP
et/FW
al./FW
,/,
2000/CD
;/:
Miwa/NNP
etal./FW
,/,
1995/CD
;/:
Nagai/NNP
etal./FW
,/,
1994/CD
;/:
Okazaki/NNP
etal./FW
,/,
1996/CD
;/:
Okuizumi/NNP
etal./FW
,/,
1995/CD
;/:
Plass/RB
etal./FW
,/,
1996/CD
;/:
Shibata/NNP
etal./FW
,/,
1995/CD
)/)
./.
====================
Although/IN
RLGS/NN
profiles/NNS
can/MD
be/VB
generated/VBN
from/IN
any/DT
high-/JJ
====================
quality/NN
genomic/JJ
DNA/NN
without/IN
prior/JJ
sequence/NN
information/NN
,/,
subsequent/JJ
cloning/NN
of/IN
RLGS/NN
fragments/NNS
is/VBZ
essential/JJ
for/IN
future/JJ
studies/NNS
./.
====================
Several/JJ
PCR-based/JJ
protocols/NNS
have/VBP
been/VBN
developed/VBN
allowing/VBG
the/DT
identification/NN
of/IN
RLGS/NN
sequences/NNS
(/(
Ohsumi/NNP
eta/NN
!/CD
./.
,/,
1995/CD
)/)
./.
====================
More/RBR
efficient/JJ
,/,
however/RB
,/,
is/VBZ
a/DT
cloning/NN
strategy/NN
that/DT
uses/VBZ
an/DT
arrayed/VBN
human/JJ
library/NN
of/IN
A/ofl/EcoRV/JJ
clones/NNS
and/CC
RLGS/NN
mixing/JJ
gel/NN
catalogs/NNS
(/(
Smiraglia/NN
et/FW
al./FW
,/,
1999/CD
)/)
./.
====================
This/DT
protocol/NN
circumvents/NNS
the/DT
need/NN
for/IN
PCR-based/JJ
amplification/NN
,/,
which/WDT
could/MD
be/VB
problematic/JJ
with/IN
GC-rich/JJ
sequences/NNS
./.
====================
Successful/JJ
use/NN
of/IN
this/DT
library/NN
system/NN
resulted/VBD
in/IN
the/DT
identification/NN
of/IN
many/JJ
methylation/NN
targets/NNS
in/IN
several/JJ
human/JJ
tumors/NNS
(/(
Costello/NN
et/FW
al./FW
,/,
2000/CD
;/:
Rush/NNP
et/FW
al./FW
,/,
2004/CD
;/:
Smiraglia/NN
and/CC
Plass/NN
2002/CD
)/)
./.
====================
The/DT
use/NN
of/IN
the/DT
A/otl/EcoRV/JJ
boundary/NN
library/NN
as/IN
a/DT
cloning/NN
tool/NN
for/IN
RLGS/NN
has/VBZ
a/DT
limitation/NN
in/IN
covering/VBG
all/DT
A/ofl-linked/JJ
clones/NNS
because/IN
the/DT
spots/NNS
on/IN
RLGS/NN
gel/NN
originates/NNS
from/IN
Noft/Noft/JJ
clones/NNS
as/IN
well/RB
as/IN
Noft/EcoRV/JJ
clones/NNS
./.
====================
To/TO
increase/VB
the/DT
potential/JJ
coverage/JJ
of/IN
CpG/NN
islands/NNS
,/,
we/PRP
prepared/VBD
a/DT
Noft/Noft/JJ
library/NN
in/IN
addition/NN
to/TO
a/DT
/Vofl/EcoRV/JJ
library/NN
and/CC
RLGS/NN
mixing/JJ
gels/NNS
that/DT
allow/VBP
the/DT
efficient/JJ
recovery/NN
of/IN
the/DT
cloned/VBN
RLGS/NN
fragments/NNS
./.
====================
We/PRP
hope/VBP
that/DT
this/DT
novel/JJ
resource/NN
,/,
together/RB
with/IN
the/DT
sequence/NN
information/NN
of/IN
the/DT
previous/JJ
/Votl/EcoRV/NN
library/NN
,/,
will/MD
greatly/RB
increase/VBP
the/DT
utility/NN
of/IN
RLGS/NN
./.
====================
We/PRP
isolated/VBD
high/JJ
molecular/JJ
weight/NN
DNA/NN
from/IN
a/DT
normal/JJ
stomach/NN
mucosa/NN
according/VBG
to/TO
the/DT
standard/JJ
protocol/NN
and/CC
performed/VBN
RLGS/NN
as/IN
previously/RB
described/VBN
(/(
Hatada/NN
etal./FW
,/,
1991/CD
)/)
./.
====================
Briefly/RB
,/,
five/CD
//g/JJ
of/IN
genomic/JJ
DNA/NN
was/VBD
blocked/VBN
in/IN
a/DT
25/CD
====================
lit/RB
reaction/NN
by/IN
adding/VBG
nucleotide/NN
analogs/NNS
(/(
[/(
ci-^SJ-dGTP/NN
,/,
[/(
a/DT
S/NN
]/)
-dCTP/NN
,/,
ddATP/NN
,/,
and/CC
ddTTP/NN
)/)
with/IN
2.5/CD
U/NNP
of/IN
DNA/NN
polymerase/NN
I/NN
(/(
TAKARA/NN
,/,
Japan/NNP
)/)
for/IN
20/CD
min/NN
at/IN
37°C/NN
,/,
followed/VBN
by/IN
inactivation/NN
of/IN
the/DT
enzyme/NN
at/IN
65°C/NN
for/IN
30/CD
min/NN
./.
====================
The/DT
DNA/NN
was/VBD
then/RB
digested/JJ
with/IN
50/CD
units/NNS
of/IN
Noft/JJ
(/(
New/NN
England/NN
BioLabs/NNS
Inc./NNP
,/,
Ipswich/JJ
,/,
MA/NN
)/)
./.
====================
We/PRP
used/VBD
Sequenase/NN
Ver/NNP
./.
====================
2.0/CD
(/(
USB/NN
,/,
Cleveland/CC
,/,
OH/NN
)/)
to/TO
fill/JJ
in/IN
the/DT
Noft/JJ
ends/NNS
with/IN
[/(
a-/RB
32/CD
P/NN
]/)
-dGTP/NN
(/(
6,000/CD
Ci/mmole/NN
;/:
NEN/NN
)/)
and/CC
[/(
a-/RB
32/CD
P/NN
]/)
-dCTP/NN
(/(
6,000/CD
Ci/mmole/NN
;/:
NEN/NN
)/)
for/IN
30/CD
min/NN
at/IN
37°C/NN
and/CC
stopped/VBD
the/DT
reaction/NN
by/IN
heating/VBG
for/IN
30/CD
min/NN
at/IN
65°C/NN
./.
====================
The/DT
labeled/JJ
DNA/NN
was/VBD
then/RB
digested/JJ
with/IN
20/CD
units/NNS
of/IN
EcoRV/NN
(/(
New/NN
England/NN
BioLabs/NNS
Inc./NNP
)/)
and/CC
separated/VBN
at/IN
8/CD
V/cm/NN
for/IN
12/CD
h/NN
in/IN
0.8/CD
%/NN
SeaKem/NN
agarose/RB
gel/NN
(/(
FMC/NN
)/)
for/IN
first-dimensional/JJ
separation/NN
./.
====================
The/DT
DNA-containing/JJ
agarose/NN
strip/NN
was/VBD
in/IN
gel/NN
digested/JJ
with/IN
1,500/CD
units/NNS
of/IN
Hinfl/JJ
(/(
New/NN
England/NN
BioLabs/NNS
Inc./NNP
)/)
for/IN
2/CD
h/NN
at/IN
37°C/NN
./.
====================
The/DT
agarose/NN
strip/NN
equilibrated/JJ
in/IN
buffer/NN
was/VBD
then/RB
placed/VBN
across/IN
the/DT
top/NN
of/IN
a/DT
non-denaturing/JJ
5/CD
%/NN
polyacrylamide/NN
gel/NN
,/,
connected/VBD
by/IN
molten/JJ
agarose/RB
,/,
and/CC
followed/VBN
by/IN
second-dimensional/JJ
electrophoresis/NN
at/IN
8/CD
V/cm/NNP
for/IN
7/CD
h./FW
After/IN
separation/NN
,/,
the/DT
gels/NNS
were/VBD
dried/VBN
and/CC
====================
exposed/VBN
to/TO
X-ray/NN
film/NN
(/(
Kodak/NN
X-OMAT/NN
)/)
in/IN
the/DT
presence/NN
of/IN
intensifying/VBG
screens/NNS
for/IN
2-10/CD
days/NNS
./.
====================
To/TO
find/VB
out/IN
which/WDT
spot/RB
originated/VBN
from/IN
the/DT
/Votl/EcoRV/NN
or/CC
the/DT
Noft/Noft/JJ
fragments/NNS
of/IN
the/DT
1st/JJ
dimension/NN
,/,
DNA/NN
digested/JJ
only/RB
with/IN
A/ofl/JJ
enzyme/NN
and/CC
the/DT
mixed/JJ
DNA/NN
containing/VBG
both/CC
/Vofl/JJ
and/CC
/Votl/EcoRV/NN
digested/JJ
DNA/NN
were/VBD
used/VBN
for/IN
RLGS/NN
analyses/NNS
./.
====================
Two/CD
RLGS/NN
profiles/NNS
from/IN
DNA/NN
digested/JJ
only/RB
with/IN
Noft/JJ
enzyme/NN
and/CC
mixed/JJ
DNA/NN
containing/VBG
both/CC
Noft/JJ
and/CC
Noft//JJ
EcoRV/NN
digested/JJ
DNA/NN
were/VBD
overlaid/VBN
,/,
and/CC
the/DT
differences/NNS
between/IN
the/DT
two/CD
profiles/NNS
were/VBD
detected/VBN
by/IN
visual/JJ
inspection/NN
and/CC
independently/RB
validated/VBD
by/IN
two/CD
investigators/NNS
./.
====================
To/TO
exclude/VB
a/DT
difficulty/NN
due/JJ
to/TO
high/JJ
density/NN
or/CC
low/JJ
resolution/NN
of/IN
spots/NNS
and/CC
to/TO
allow/VB
the/DT
uniform/JJ
comparison/NN
of/IN
RLGS/NN
profiles/NNS
from/IN
different/JJ
samples/NNS
,/,
we/PRP
compared/VBD
spots/NNS
only/RB
on/IN
the/DT
central/JJ
portion/NN
of/IN
the/DT
RLGS/NN
profile/NN
./.
====================
To/TO
generate/VB
Noft/EcoRV/NN
and/CC
Noft/Noft/JJ
libraries/NNS
as/IN
a/DT
resource/NN
to/TO
facilitate/VB
the/DT
analysis/NN
of/IN
RLGS/NN
loci/NNS
,/,
one/CD
hundred/VBN
//g/NN
of/IN
normal/JJ
mucosa/NN
tissue/NN
was/VBD
doubly/RB
digested/JJ
with/IN
Noft/EcoRV/JJ
and/CC
the/DT
resulting/VBG
fragments/NNS
were/VBD
purified/VBN
by/IN
using/VBG
the/DT
phenol/ethanol/NN
extraction/NN
method/NN
./.
====================
First/RB
,/,
to/TO
exclude/VB
EcoRV-EcoRV/NN
DNA/NN
fragments/NNS
in/IN
DNA/NN
solution/NN
,/,
X-ZAPII/NN
DNA/NN
(/(
22.12/CD
kb/NN
)/)
was/VBD
digested/VBN
with/IN
Noft/JJ
enzyme/NN
and/CC
its/PRP$
Noft/JJ
end/NN
was/VBD
treated/VBN
with/IN
CIP/NN
(/(
TAKARA/NN
)/)
./.
====================
The/DT
X-ZAPII/A/ofl/JJ
DNA/NN
was/VBD
ligated/VBN
with/IN
genomic/JJ
DNA/NN
and/CC
then/RB
digested/JJ
with/IN
EcoRV/NN
to/TO
separate/VB
fragments/NNS
ligated/VBN
at/IN
EcoRV/NN
sites/NNS
./.
====================
The/DT
mixtures/NNS
were/VBD
run/JJ
on/IN
0.8/CD
%/NN
LMP/NN
agarose/RB
(/(
FMC/NN
)/)
gel/NN
and/CC
the/DT
portion/NN
of/IN
the/DT
gel/NN
over/IN
22/CD
kb/NN
was/VBD
eluted/VBN
and/CC
purified/VBN
with/IN
beta-agarase/NN
I/NN
(/(
New/NN
England/NN
BioLabs/NNS
Inc./NNP
)/)
./.
====================
This/DT
DNA/NN
was/VBD
digested/VBN
with/IN
Noft/JJ
,/,
run/JJ
on/IN
1/CD
%/NN
LMP/NN
agarose/RB
gel/NN
,/,
and/CC
fragments/NNS
ranging/VBG
0.7/CD
to/TO
4/CD
kb/NN
were/VBD
eluted/VBN
by/IN
usinga/VBG
Gel/NN
Extraction/NN
kit/NN
(/(
Qiagen/NN
)/)
./.
====================
The/DT
resulting/VBG
DNA/NN
solution/NN
was/VBD
then/RB
divided/VBN
into/IN
two/CD
tubes/NNS
:/:
DNA/NN
fragments/NNS
from/IN
one/CD
tube/NN
were/VBD
ligated/VBN
into/IN
pBluescript/NN
KS/NN
(/(
+/CC
)/)
DNA/NN
digested/JJ
with/IN
Noft/JJ
and/CC
EcoRV/NN
and/CC
the/DT
other/JJ
fragments/NNS
were/VBD
ligated/VBN
into/IN
pBluescript/NN
KS/NN
(/(
+/CC
)/)
digested/JJ
only/RB
with/IN
Noft/JJ
./.
====================
The/DT
solutions/NNS
were/VBD
transformed/VBN
into/IN
DH5a/NN
cells/NNS
by/IN
electroporation/NN
./.
====================
Finally/RB
,/,
we/PRP
prepared/VBD
two/CD
kinds/NNS
of/IN
Noft/JJ
-linked/JJ
DNA/NN
library/NN
,/,
Noft/Noft/JJ
DNA/NN
library/NN
(/(
'NN/NNP
1/CD
)/)
and/CC
Noft//JJ
EcoRV/NN
DNA/NN
library/NN
(/(
'NE/NNP
'/``
)/)
of/IN
0.7/CD
to/TO
4/CD
kb/NN
fragments/NNS
comprising/VBG
the/DT
central/JJ
portion/NN
of/IN
the/DT
RLGS/NN
gel/NN
(/(
Fig/NN
./.
====================
2/CD
)/)
./.
====================
Plasmid/NN
DNAs/NNS
from/IN
all/DT
clones/NNS
of/IN
NN/NN
and/CC
NE/NN
libraries/NNS
were/VBD
isolated/VBN
by/IN
using/VBG
a/DT
MWG/NN
plasmidprep/NN
96/CD
(/(
MWG/NN
Biotech/NNP
./.
)/)
./.
====================
Sequencing/NN
reactions/NNS
were/VBD
performed/VBN
on/IN
a/DT
====================
GeneAmp/NN
PCR/NN
System/NN
9700/CD
thermal/JJ
reactor/NN
(/(
Perkin-/NN
Elmer/NN
Corp./NN
)/)
by/IN
using/VBG
a/DT
BigDye/NN
Terminator/NN
Sequencing/NN
kit/NN
with/IN
T7/NN
sequencing/NN
primer/NN
to/TO
get/VB
Noft/JJ
end/NN
sequences/NNS
./.
====================
After/IN
removing/VBG
the/DT
unincorporated/JJ
dye/NN
terminator/NN
,/,
the/DT
reaction/NN
products/NNS
were/VBD
run/JJ
on/IN
an/DT
ABI/NN
prism/NN
3700/CD
DNA/NN
analyzer/NN
(/(
Perkin-Elmer/NN
Corp./NN
)/)
./.
====================
DNA/NN
sequences/NNS
were/VBD
assembled/VBN
to/TO
isolate/VB
unique/JJ
/Vofl-linked/JJ
clones/NNS
by/IN
using/VBG
DNASTAR/NN
software/JJ
./.
====================
BLAT/NN
search/VBP
for/IN
unique/JJ
sequences/NNS
were/VBD
performed/VBN
on/IN
the/DT
UCSC/NN
genome/NN
server/RB
,/,
May/NNP
2004/CD
Freeze/JJ
(/(
http/NN
:/:
//genome.ucsc.edu/cgi-birVhgBlat/JJ
)/)
to/TO
determine/VB
whether/IN
the/DT
sequences/NNS
fall/DT
in/IN
a/DT
known/JJ
CpG/NN
island/NN
or/CC
reported/VBN
gene/NN
region/NN
./.
====================
Plasmid/NN
DNAs/NNS
with/IN
unique/JJ
/Vod-linked/JJ
sequences/NNS
were/VBD
arrayed/VBN
into/IN
12/CD
96-well/JJ
microtiter/NN
plates/VBZ
for/IN
their/PRP$
use/NN
in/IN
the/DT
RLGS/NN
mixing/JJ
gels/NNS
./.
====================
The/DT
DNAs/NNS
were/VBD
pooled/JJ
in/IN
three/CD
different/JJ
ways/NNS
:/:
by/IN
plate/NN
,/,
by/IN
row/JJ
,/,
and/CC
by/IN
column/NN
,/,
as/IN
described/VBN
previously/RB
(/(
Smiraglia/NN
et/FW
al./FW
,/,
1999/CD
)/)
./.
====================
The/DT
96/CD
plasmid/NN
DNAs/NNS
from/IN
each/DT
of/IN
the/DT
12/CD
plates/VBZ
were/VBD
pooled/JJ
into/IN
12/CD
microtubes/NNS
./.
====================
The/DT
8/CD
rows/VBZ
(/(
A-H/NN
)/)
from/IN
each/DT
of/IN
the/DT
12/CD
plates/VBZ
were/VBD
also/RB
pooled/VBD
into/IN
new/JJ
microtiter/NN
plates/VBZ
by/IN
using/VBG
a/DT
12-channel/NN
pipette/NN
and/CC
finally/RB
transferred/VBN
into/IN
8/CD
====================
microtubes/NNS
./.
====================
The/DT
12/CD
columns/NNS
(/(
1-12/CD
)/)
from/IN
each/DT
of/IN
the/DT
12/CD
plates/VBZ
were/VBD
similarly/RB
pooled/JJ
by/IN
using/VBG
an/DT
8-channel/NN
pipette/NN
and/CC
finally/RB
transferred/VBN
into/IN
12/CD
microtubes/NNS
./.
====================
In/IN
total/JJ
,/,
32/CD
pooled/JJ
DNAs/NNS
were/VBD
labeled/VBN
according/VBG
to/TO
the/DT
standard/JJ
RLGS/NN
procedure/NN
and/CC
mixed/JJ
with/IN
the/DT
labeled/VBN
genomic/JJ
DNA/NN
when/WRB
the/DT
first/JJ
dimensional/JJ
agarose/RB
gel/NN
was/VBD
loaded/VBN
./.
====================
The/DT
standard/JJ
RLGS/NN
procedure/NN
described/VBN
above/IN
was/VBD
continued/VBN
./.
====================
We/PRP
generated/VBD
a/DT
standard/JJ
RLGS/NN
profile/NN
for/IN
DNAs/NNS
from/IN
a/DT
normal/JJ
mucosa/NN
and/CC
divided/VBN
the/DT
profile/NN
into/IN
30/CD
sections/NNS
to/TO
allow/VB
a/DT
uniform/JJ
comparison/NN
of/IN
RLGS/NN
profiles/NNS
from/IN
different/JJ
samples/NNS
./.
====================
Then/RB
each/DT
fragment/NN
was/VBD
given/VBN
a/DT
three-variable/JJ
designation/NN
(/(
Y/NN
coordinate/VBP
,/,
X/NN
coordinate/JJ
,/,
fragment/NN
number/NN
)/)
./.
====================
The/DT
central/JJ
region/NN
of/IN
the/DT
RLGS/NN
profile/NN
had/VBD
30/CD
sections/NNS
(/(
18/CD
vertically/RB
and/CC
A-D/NN
horizontally/RB
)/)
,/,
containing/VBG
1,948/CD
spots/NNS
(/(
Fig/NN
./.
====================
1/CD
A/NN
)/)
./.
====================
The/DT
1A/NN
and/CC
2A/NN
sections/NNS
were/VBD
excluded/VBN
because/IN
there/EX
was/VBD
no/DT
fragment/NN
in/IN
those/DT
sections/NNS
./.
====================
A/DT
standard/JJ
RLGS/NN
profile/NN
,/,
on/IN
which/WDT
individual/JJ
spot/NN
number/NN
was/VBD
assigned/VBN
and/CC
is/VBZ
available/JJ
at/IN
http/NN
:/:
//21cgenome.kribb.re.kr/html/2004_new/RLGS_ma/NN
ster/i/NN
mage01.html/NN
./.
====================
We/PRP
found/VBD
that/IN
404/CD
spots/NNS
in/IN
the/DT
central/JJ
portion/NN
of/IN
the/DT
standard/JJ
RLGS/NN
profile/NN
originated/VBN
from/IN
Noh/Noh/JJ
DNA/NN
fragments/NNS
(/(
Fig/NN
./.
====================
1B/NN
)/)
./.
====================
Most/JJS
of/IN
the/DT
Noh/Noh/JJ
DNA/NN
fragments/NNS
reappeared/VBN
in/IN
the/DT
RLGS/NN
profile/NN
originated/VBN
from/IN
Noh//JJ
EcoRV/NN
DNA/NN
fragments/NNS
(/(
Fig/NN
./.
====================
1C/NN
)/)
./.
====================
This/DT
result/NN
indicates/VBZ
that/IN
20.7/CD
%/NN
(/(
404/CD
of/IN
1948/CD
spots/NNS
)/)
on/IN
the/DT
standard/JJ
RLGS/NN
profile/NN
====================
originated/VBN
from/IN
Noh/Noh/JJ
DNA/NN
fragments/NNS
and/CC
that/IN
Noh/Noll/NN
DNA/NN
fragments/NNS
are/VBP
also/RB
important/JJ
parts/NNS
of/IN
the/DT
Noh/EcoRN/JJ
DNA/NN
fragments/NNS
./.
====================
To/TO
identify/VB
Noh/Noh/JJ
as/IN
well/RB
as/IN
Noh/EcoRV/JJ
DNA/NN
fragments/NNS
as/IN
a/DT
resource/NN
to/TO
facilitate/VB
the/DT
analysis/NN
of/IN
RLGS/NN
loci/NNS
,/,
we/PRP
established/VBD
an/DT
'NN/NN
library/NN
'/``
and/CC
an/DT
'NE/NN
library/NN
'/``
containing/VBG
Noh/Noh/JJ
and/CC
Noh/EcoR\f/JJ
fragments/NNS
ranging/VBG
from/IN
0.7/CD
to/TO
4/CD
kb/NN
(/(
Fig/NN
./.
====================
2/CD
)/)
./.
====================
We/PRP
collected/VBD
a/DT
total/JJ
of/IN
5,255/CD
white/JJ
colonies/NNS
,/,
of/IN
which/WDT
4,328/CD
were/VBD
from/IN
the/DT
NE/NN
library/NN
and/CC
927/CD
from/IN
the/DT
NN/NN
library/NN
,/,
and/CC
determined/VBN
their/PRP$
/Vofl-end/NN
sequences/NNS
./.
====================
All/DT
A/ofl-end/NN
sequences/NNS
were/VBD
assembled/VBN
to/TO
select/VB
unique/JJ
sequences/NNS
by/IN
using/VBG
DNASTAR/NN
software/JJ
./.
====================
Totally/RB
1,161/CD
unique/JJ
sequences/NNS
(/(
or/CC
clones/NNS
)/)
were/VBD
isolated/VBN
;/:
1,051/CD
sequences/NNS
were/VBD
isolated/VBN
from/IN
the/DT
NE/NN
library/NN
and/CC
110/CD
from/IN
the/DT
NN/NN
library/NN
./.
====================
The/DT
sequence/NN
data/NNS
were/VBD
submitted/VBN
to/TO
NCBI/NN
GenBank/NN
as/IN
accession/NN
numbers/NNS
CG464575-CG465835/NN
./.
====================
The/DT
average/JJ
insert/NN
size/NN
for/IN
unique/JJ
clones/NNS
was/VBD
approximately/RB
1.5/CD
kb/NN
(/(
n/NN
=/JJ
860/CD
)/)
ranging/VBG
from/IN
0.7/CD
to/TO
4/CD
kb/NN
and/CC
average/NN
read/VBN
length/NN
was/VBD
423/CD
bp/NN
./.
====================
The/DT
unique/JJ
clones/NNS
were/VBD
estimated/VBN
to/TO
cover/VB
60/CD
%/NN
of/IN
the/DT
1,948/CD
RLGS/NN
spots/NNS
(/(
Table/JJ
1/CD
)/)
./.
====================
To/TO
identify/VB
potential/JJ
genes/NNS
or/CC
CpG/NN
islands/NNS
linked/VBN
with/IN
the/DT
above/JJ
1,161/CD
unique/JJ
sequences/NNS
,/,
we/PRP
performed/VBD
BLAT/NN
searches/VBZ
on/IN
the/DT
UCSC/NN
genome/NN
server/RB
,/,
May/NNP
2004/CD
Freeze/JJ
(/(
http/NN
:/:
//genome.ucsc.edu/cgi-bin/hgBlat/JJ
)/)
./.
====================
1,023/CD
(/(
88/CD
%/NN
)/)
unique/JJ
sequences/NNS
were/VBD
matched/VBN
to/TO
UCSC/NN
CpG/NN
islands/NNS
,/,
of/IN
which/WDT
919/CD
(/(
87/CD
%/NN
)/)
were/VBD
derived/VBN
from/IN
NE/NN
clones/NNS
and/CC
104/CD
(/(
95/CD
%/NN
)/)
from/IN
NN/NN
clones/NNS
./.
====================
We/PRP
also/RB
found/VBD
that/IN
646/CD
(/(
70/CD
%/NN
)/)
sequences/NNS
matched/VBN
to/TO
UCSC/NN
CpG/NN
islands/VBZ
were/VBD
in/IN
the/DT
Send/NN
of/IN
genes/NNS
,/,
136/CD
(/(
15/CD
%/NN
)/)
were/VBD
in/IN
the/DT
3/CD
'/``
end/NN
of/IN
genes/NNS
,/,
and/CC
27/CD
(/(
3/LS
%/NN
)/)
were/VBD
intragenic/JJ
regions/NNS
,/,
and/CC
110/CD
(/(
12/CD
%/NN
)/)
were/VBD
not/RB
linked/VBN
to/TO
any/DT
gene/NN
./.
====================
This/DT
result/NN
is/VBZ
similar/JJ
to/TO
the/DT
previous/JJ
report/NN
that/IN
8,239/CD
(/(
86/CD
%/NN
)/)
of/IN
9,628/CD
Noh/JJ
sites/NNS
estimated/VBN
from/IN
human/JJ
genome/NN
draft/NN
sequence/NN
were/VBD
linked/VBN
to/TO
CpG/NN
islands/NNS
(/(
Dai/NN
et/FW
al./FW
,/,
====================
2002/CD
)/)
,/,
showing/VBG
a/DT
large/JJ
bias/NNS
of/IN
RLGS/NN
toward/IN
identifying/VBG
potential/JJ
genes/NNS
or/CC
CpG/NN
islands/NNS
./.
====================
It/PRP
is/VBZ
worthy/RB
to/TO
note/VB
that/IN
the/DT
/Vofl-loci/NNS
we/PRP
cloned/VBD
have/VBP
a/DT
high/JJ
frequency/NN
(/(
71/CD
%/NN
)/)
of/IN
occurrence/NN
within/IN
CpG/NN
islands/VBZ
near/JJ
the/DT
5/CD
1/CD
ends/VBZ
of/IN
known/JJ
genes/NNS
rather/RB
than/IN
within/IN
CpG/NN
islands/VBZ
near/JJ
the/DT
3/CD
'/``
ends/NNS
or/CC
intra-genic/JJ
regions/NNS
,/,
thus/RB
making/VBG
RLGS/NN
a/DT
potent/JJ
tool/NN
for/IN
====================
the/DT
identification/NN
of/IN
gene-associated/VBN
methylation/NN
events/NNS
./.
====================
Several/JJ
groups/NNS
generated/VBD
RLGS/NN
profiles/NNS
from/IN
many/JJ
types/NNS
of/IN
cancer/NN
and/CC
reported/VBD
interesting/JJ
genes/NNS
(/(
Costello/NN
et/FW
al./FW
,/,
2000/CD
;/:
Smiraglia/NN
et/FW
al./FW
,/,
1999/CD
;/:
Zardo/NNP
et/FW
al./FW
,/,
2002/CD
)/)
./.
====================
However/RB
,/,
because/IN
previous/JJ
studies/NNS
used/VBD
only/RB
/Vo/I//JJ
EcoRV/NN
DNA/NN
fragments/NNS
for/IN
mixing/JJ
gel/NN
catalog/NN
,/,
they/PRP
have/VBP
====================
limitations/NNS
in/IN
identifying/VBG
novel/JJ
epigenetic/JJ
targets/NNS
./.
====================
Thus/RB
,/,
our/PRP$
A/otl-linked/JJ
sequences/NNS
including/VBG
Notl/Noti/NN
as/IN
well/RB
as/IN
A/ofl/EcoRV/JJ
DNA/NN
fragments/NNS
may/MD
be/VB
helpful/JJ
to/TO
give/VB
additional/JJ
information/NN
on/IN
RLGS/NN
study/NN
./.
====================
To/TO
identify/VB
each/DT
unique/JJ
/Vofl-linked/JJ
clone/NN
on/IN
the/DT
RLGS/NN
gel/NN
,/,
all/DT
unique/JJ
clones/NNS
were/VBD
arrayed/VBN
into/IN
12/CD
96-well/JJ
microtiter/NN
plates/VBZ
and/CC
RLGS/NN
mixing/JJ
gels/NNS
were/VBD
prepared/VBN
from/IN
plates/NNS
1/CD
to/TO
12/CD
./.
====================
Not\/Not\/RB
clones/NNS
from/IN
multi-copy/JJ
rDNA/JJ
were/VBD
excluded/VBN
in/IN
this/DT
step/NN
because/IN
the/DT
positions/NNS
of/IN
Not\/Not\/NN
fragments/NNS
derived/VBN
from/IN
genomic/JJ
rDNA/NN
are/VBP
already/RB
known/VBN
(/(
Kuick/NNP
etal./FW
,/,
1996/CD
)/)
./.
====================
The/DT
rows/NNS
and/CC
columns/NNS
from/IN
these/DT
12/CD
plates/VBZ
were/VBD
individually/RB
pooled/JJ
to/TO
produce/VB
mixing/JJ
gels/NNS
as/IN
previously/RB
described/VBN
(/(
Smiraglia/NN
et/FW
al./FW
,/,
1999/CD
)/)
./.
====================
In/IN
total/JJ
,/,
32/CD
RLGS/NN
mixing/JJ
gels/NNS
were/VBD
produced/VBN
./.
====================
In/IN
the/DT
RLGS/NN
mixing/JJ
gels/NNS
,/,
spots/NNS
will/MD
be/VB
shown/VBN
as/IN
enhanced/VBN
if/IN
the/DT
corresponding/JJ
clone/NN
is/VBZ
present/JJ
in/IN
the/DT
pool/NN
of/IN
clones/NNS
mixed/VBN
with/IN
the/DT
genomic/JJ
DNA/NN
./.
====================
The/DT
determination/NN
of/IN
the/DT
plate/NN
,/,
row/JJ
,/,
and/CC
column/NN
of/IN
the/DT
mixing/JJ
gels/NNS
in/IN
which/WDT
the/DT
RLGS/NN
spot/NN
of/IN
interest/NN
is/VBZ
enhanced/VBN
indicates/VBZ
the/DT
address/NN
of/IN
the/DT
unique/JJ
clone/NN
in/IN
which/WDT
the/DT
corresponding/JJ
RLGS/NN
fragment/NN
was/VBD
cloned/VBN
./.
====================
Table/JJ
2./FW
shows/VBZ
the/DT
sequence/NN
information/NN
for/IN
151/CD
unique/JJ
clones/NNS
identified/VBD
by/IN
using/VBG
the/DT
RLGS/NN
mixing/JJ
gels/NNS
./.
====================
We/PRP
compared/VBD
the/DT
spot/NN
positions/NNS
in/IN
this/DT
study/NN
to/TO
the/DT
master/JJ
RLGS/NN
profiles/NNS
in/IN
previous/JJ
work/NN
(/(
Costello/NN
etal./FW
,/,
2000/CD
)/)
and/CC
the/DT
methylated/JJ
RLGS/NN
spots/NNS
found/VBN
in/IN
various/JJ
tumor/NN
types/NNS
in/IN
previous/JJ
literatures/NNS
./.
====================
Costello/NN
etal/JJ
./.
====================
(/(
2000/CD
)/)
have/VBP
shown/VBN
that/IN
4C06/CD
,/,
3B71/NNP
,/,
6D05/CD
,/,
and/CC
4B84/CD
(/(
3D60/CD
,/,
3C02/NN
,/,
5E12/NN
,/,
and/CC
4B05/CD
in/IN
Master/NNP
RLGS/NN
)/)
were/VBD
CpG/NN
islands/VBZ
affected/VBN
in/IN
at/IN
least/JJS
three/CD
different/JJ
tumor/NN
types/NNS
:/:
4C06/CD
in/IN
colon/NN
carcinoma/NN
,/,
glioma/NN
,/,
and/CC
acute/JJ
myeloid/JJ
leukemia/NN
;/:
3B71/RB
in/IN
colon/NN
carcinoma/NN
,/,
head/RB
and/CC
neck/NN
squamous/JJ
cell/NN
carcinoma/NN
,/,
and/CC
acute/JJ
myeloid/JJ
leukemia/NN
;/:
6D05/CD
in/IN
breast/NN
carcinoma/NN
,/,
glioma/NN
,/,
and/CC
acute/JJ
myeloid/JJ
leukemia/NN
;/:
4B84/CD
in/IN
breast/NN
carcinoma/NN
,/,
colon/NN
carcinoma/NN
,/,
and/CC
glioma/NN
./.
====================
They/PRP
have/VBP
also/RB
shown/VBN
that/IN
3B80,6C26,4B51/CD
and/CC
5D84/CD
(/(
3C17/CD
,/,
5D13/CD
,/,
3C67/CD
and/CC
4F55/CD
in/IN
Master/JJ
RLGS/NN
)/)
were/VBD
affected/VBN
at/IN
a/DT
high/JJ
frequency/NN
in/IN
one/CD
tumor/NN
type/NN
but/CC
infrequently/RB
in/IN
others/NNS
,/,
thus/RB
suggesting/VBG
that/IN
some/DT
CpG-island/NN
targets/NNS
are/VBP
methylated/VBN
in/IN
a/DT
tumor-type/JJ
specific/JJ
manner/NN
while/IN
others/NNS
are/VBP
shared/VBN
by/IN
multiple/JJ
tumor/NN
types/NNS
./.
====================
In/IN
addition/NN
,/,
the/DT
methylation/JJ
of/IN
4C55/CD
,/,
5C10,5C30,2C46,3B43,3B79/CD
and/CC
3B13/RB
have/VBP
been/VBN
found/VBN
in/IN
hepatocellular/JJ
carcinoma/NN
(/(
Nagai/NNP
etal./FW
,/,
1994/CD
)/)
;/:
the/DT
methylation/JJ
of/IN
6D27/NN
and/CC
3D85/RB
in/IN
lung/NN
carcinoma/NN
(/(
Smiraglia/NNP
etal./FW
,/,
2001/CD
;/:
Dai/NNP
etal./FW
,/,
2001/CD
)/)
;/:
the/DT
methylation/JJ
of/IN
4B63/CD
and/CC
3D85/RB
in/IN
acute/JJ
myeloid/JJ
leukemia/NN
(/(
Rush/NNP
etal./FW
,/,
2001/CD
)/)
;/:
the/DT
methylation/JJ
of/IN
2B16/CD
in/IN
glioma/NN
(/(
Nakamura/NNP
etal./FW
,/,
1997/CD
)/)
;/:
the/DT
methylation/JJ
of/IN
6C26/DT
,/,
3D85/NNP
and/CC
5B06/CD
in/IN
chronic/JJ
lymphocytic/JJ
leukemia/NN
(/(
Rush/NNP
et/FW
al./FW
,/,
2004/CD
)/)
;/:
the/DT
methylation/JJ
of/IN
4A44/CD
and/CC
3B13/RB
in/IN
renal/JJ
cell/NN
carcinoma/NN
(/(
Cho/NNP
et/FW
al./FW
,/,
1998/CD
)/)
./.
====================
Aberrant/JJ
methylation/NN
of/IN
CpG/NN
islands/NNS
containing/VBG
the/DT
promoters/NNS
of/IN
cancer-related/JJ
====================
genes/NNS
is/VBZ
often/RB
associated/VBN
with/IN
transcriptional/JJ
inactivation/NN
(/(
Baylin/NN
etal./FW
,/,
1998/CD
;/:
Jones/NNS
and/CC
Laird/JJ
,/,
1999/CD
)/)
./.
====================
The/DT
methylated/JJ
CpG/NN
islands/NNS
in/IN
various/JJ
tumors/NNS
cloned/VBN
here/RB
may/MD
be/VB
novel/JJ
epigenetic/JJ
targets/NNS
for/IN
the/DT
corresponding/JJ
tumors/NNS
,/,
because/IN
no/DT
information/NN
on/IN
them/PRP
has/VBZ
been/VBN
found/VBN
in/IN
literatures/NNS
./.
====================
Thus/RB
,/,
it/PRP
is/VBZ
required/VBN
to/TO
determine/VB
whether/IN
the/DT
methylation/NN
events/NNS
reported/VBN
here/RB
have/VBP
an/DT
impact/NN
on/IN
transcription/NN
of/IN
those/DT
genes/NNS
./.
====================
In/IN
conclusion/NN
,/,
we/PRP
assessed/VBD
sequence/NN
information/NN
for/IN
A/ofl/JJ
sequences/NNS
on/IN
a/DT
standard/JJ
RLGS/NN
gel/NN
./.
====================
We/PRP
cloned/VBD
1,023/CD
individual/JJ
A/ofl-linked/JJ
sequences/NNS
matched/VBN
to/TO
CpG/NN
islands/NNS
of/IN
human/JJ
genome/NN
,/,
showing/VBG
a/DT
high/JJ
frequency/NN
of/IN
occurrence/NN
within/IN
CpG/NN
islands/NNS
near/JJ
the/DT
5/CD
'/``
ends/NNS
of/IN
known/JJ
genes/NNS
rather/RB
than/IN
within/IN
CpG/NN
islands/NNS
near/JJ
the/DT
3/CD
'/``
ends/NNS
or/CC
intra-genic/JJ
regions/NNS
./.
====================
This/DT
information/NN
is/VBZ
available/JJ
for/IN
the/DT
identification/NN
of/IN
gene-associated/VBN
methylation/NN
events/NNS
./.
====================
We/PRP
also/RB
provide/VBP
151/CD
Not\/NN
sequences/NNS
onto/IN
a/DT
standard/JJ
RLGS/NN
gel/NN
with/IN
previous/JJ
methylation/NN
events/NNS
from/IN
several/JJ
type/NN
of/IN
tumor/NN
./.
====================
Therefore/RB
,/,
our/PRP$
sequence/NN
information/NN
may/MD
be/VB
very/RB
useful/JJ
to/TO
identify/VB
novel/JJ
epigenetic/JJ
targets/NNS
in/IN
many/JJ
tumor/NN
types/NNS
./.
====================
